Abstract
Current technologies for the purification of supercoiled plasmids are limited. The use of cesium chloride gradients in the presence of ethidium bromide is time consuming, labor intensive, requires the use of known mutagens and is not conducive to large scale. As a result, first-generation high-performance liquid chromatography (HPLC) methods based on anion-exchange and size exclusion have been developed but are difficult to accommodate production at large scale and still result in compromised purity (1,2). The success of DNA vaccines in animal models and the initiation of human trials (3,4) has led to a need to increase the level of supercoiled plasmid purity as well as the methodology utilized to produce these plasmids at large scale. Several parameters of the purification process need to be addressed:
-
• The ability to prepare supercoiled plasmid at purity levels acceptable for clinical material.
-
• The ability to prepare clinical grade supercoiled plasmid that will be scalable in order to produce gram quantities of product.
-
• The ability to prepare clinical grade supercoiled plasmid in accordance with cGMP principles.
-
• The ability to develop validated assays to assess purity, yield, and contamination levels.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Green, A. P., Prior, G. P., Helveston, N. M., Taittinger, B. E., Liu, X.-F., and Thompson, J. A. (1997). Preparative purification of supercoiled plasmid DNA for therapeutic applications. BioPharm 10, 52–62.
Horn, N. A., Meek, J. A., Budahazi, G., and Marquet, M. (1995). Cancer gene therapy using plasmid DNA: purification and DNA for human clinical trials. Hum. Gene Ther. 6, 565–573.
Ulmer, J. B., Donnelly, J. J., and Liu, M. (1996). Toward the development of DNA vaccines. Curr. Opin. Biotechnol. 7, 653–658.
Donnelly, J. J., Ulmer, J. B., Shiver, J. W., and Liu, M. (1997). DNA vaccines. Ann. Rev. Immunol. 15, 617–648.
Weber, M., Möller, K., Welzeck, M., and Schoor, J. (1995). Effects of lipopolysaccharide on transfection efficiency in eukaryotic cell. BioTechniques 19, 930–940.
Wicks, I. P., Howell, M. L., Hancock, T., Kohsaka, H., Olee, T.-W., and Carson, D. (1995). Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy. Hum. Gene Ther. 6, 317–323.
Birnbaum, H. C. and Doly, J. (1979). A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7, 1513–1523.
Lahijani, R., Hulley, G., Soriano, G., Horn, N., and Marquet, M. (1996). Highyield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum. Gene Ther. 7, 1971–1980.
Thompson, and Blakesley, (1983). Purification of nucleic acids by RPC-5 analog chromatography: peristaltic and gravity-flow applications. Meth. Enzymol. 110, 123–127.
Office of Vaccine Research and Review (1996). Points to consider on plasmid DNA vaccines for preventive infectious disease indications, Food and Drug Administration, Bethesda, MD.
Middaugh, C. R., Evans, R. K., Montgomery, D. L., and Casimiro, D. R. (1998). Analysis of plasmid DNA from a pharmaceutical perspective. J. Pharm. Sci. 8, 130–146.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Green, A.P. (2000). Purification of Supercoiled Plasmid. In: Lowrie, D.B., Whalen, R.G. (eds) DNA Vaccines. Methods in Molecular Medicine™, vol 29. Humana Press. https://doi.org/10.1385/1-59259-688-6:1
Download citation
DOI: https://doi.org/10.1385/1-59259-688-6:1
Publisher Name: Humana Press
Print ISBN: 978-0-89603-580-5
Online ISBN: 978-1-59259-688-1
eBook Packages: Springer Protocols